Cyclo Short Term Investments vs Other Current Liab Analysis

CYTH Stock

USD 0.68 0.04 6.23%

Cyclo Therapeutics financial indicator trend analysis is way more than just evaluating Cyclo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclo Therapeutics is a good investment. Please check the relationship between Cyclo Therapeutics Short Term Investments and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Short Term Investments vs Other Current Liab

Short Term Investments vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclo Therapeutics Short Term Investments account and Other Current Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Cyclo Therapeutics' Short Term Investments and Other Current Liab is -0.24. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Cyclo Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclo Therapeutics' Short Term Investments and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of Cyclo Therapeutics are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Short Term Investments i.e., Cyclo Therapeutics' Short Term Investments and Other Current Liab go up and down completely randomly.

Correlation Coefficient

-0.24

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Short Term Investments

Short Term Investments is an item under the current assets section of Cyclo Therapeutics balance sheet. It contains any investments Cyclo Therapeutics undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Cyclo Therapeutics can easily liquidate in the marketplace.

Other Current Liab

Most indicators from Cyclo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Issuance Of Capital Stock is increasing as compared to previous years. The Cyclo Therapeutics' current Sales General And Administrative To Revenue is estimated to increase to 5.52, while Selling General Administrative is projected to decrease to under 2.9 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	15.7M	16.8M	17.6M	18.5M
Cost Of Revenue	156.1K	138.9K	3.5M	3.7M

Total Operating Expenses Cost Of Revenue

Cyclo Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Other Current Liab	Short Term Investments	Current Deferred Revenue
Total Assets		0.15	0.74	0.85	-0.22	-0.96	-0.71	0.81	0.98	-0.28	-0.35	0.98	0.68	0.64	-0.23	-0.16	0.53	0.79	0.73	0.99	0.4	-0.28	-0.42	0.49	-0.3	-0.52
Short Long Term Debt Total	0.15		0.41	-0.15	0.61	0.11	-0.39	0.14	-0.03	0.57	0.31	-0.03	-0.32	0.58	0.41	-0.14	0.45	0.37	0.47	0.04	0.76	-0.21	-0.37	-0.54	-0.23	0.3
Total Current Liabilities	0.74	0.41		0.29	-0.27	-0.64	-0.95	0.94	0.68	-0.34	-0.48	0.68	0.25	0.94	-0.07	-0.2	0.74	0.95	0.99	0.75	0.79	-0.23	-0.18	0.33	-0.27	-0.6
Total Stockholder Equity	0.85	-0.15	0.29		-0.15	-0.89	-0.3	0.45	0.88	-0.19	-0.19	0.88	0.79	0.18	-0.26	-0.04	0.2	0.4	0.28	0.84	-0.04	-0.23	-0.43	0.5	-0.23	-0.33
Property Plant And Equipment Net	-0.22	0.61	-0.27	-0.15		0.42	0.39	-0.49	-0.35	0.99	0.73	-0.35	-0.35	-0.17	0.03	0.12	-0.35	-0.38	-0.22	-0.36	0.05	-0.12	-0.09	-0.68	-0.12	0.85
Net Debt	-0.96	0.11	-0.64	-0.89	0.42		0.63	-0.79	-0.99	0.47	0.46	-0.99	-0.74	-0.5	0.28	0.16	-0.45	-0.71	-0.62	-0.98	-0.22	0.2	0.37	-0.65	0.22	0.63
Retained Earnings	-0.71	-0.39	-0.95	-0.3	0.39	0.63		-0.91	-0.66	0.46	0.56	-0.66	-0.3	-0.95	-0.17	0.23	-0.9	-0.99	-0.94	-0.74	-0.82	0.24	0.29	-0.35	0.28	0.7
Accounts Payable	0.81	0.14	0.94	0.45	-0.49	-0.79	-0.91		0.8	-0.55	-0.6	0.8	0.44	0.81	-0.13	-0.26	0.7	0.93	0.93	0.85	0.58	-0.24	-0.13	0.59	-0.27	-0.76
Cash	0.98	-0.03	0.68	0.88	-0.35	-0.99	-0.66	0.8		-0.4	-0.42	1.0	0.71	0.55	-0.29	-0.17	0.46	0.74	0.67	0.99	0.28	-0.22	-0.39	0.6	-0.23	-0.58
Non Current Assets Total	-0.28	0.57	-0.34	-0.19	0.99	0.47	0.46	-0.55	-0.4		0.8	-0.4	-0.36	-0.24	0.03	0.12	-0.41	-0.45	-0.28	-0.42	-0.03	-0.15	-0.04	-0.68	-0.14	0.86
Non Currrent Assets Other	-0.35	0.31	-0.48	-0.19	0.73	0.46	0.56	-0.6	-0.42	0.8		-0.42	-0.25	-0.4	-0.01	0.02	-0.49	-0.55	-0.42	-0.46	-0.28	-0.19	0.03	-0.56	-0.17	0.7
Cash And Short Term Investments	0.98	-0.03	0.68	0.88	-0.35	-0.99	-0.66	0.8	1.0	-0.4	-0.42		0.71	0.55	-0.29	-0.17	0.46	0.74	0.67	0.99	0.28	-0.22	-0.39	0.6	-0.23	-0.58
Net Receivables	0.68	-0.32	0.25	0.79	-0.35	-0.74	-0.3	0.44	0.71	-0.36	-0.25	0.71		0.18	-0.25	-0.07	0.22	0.37	0.23	0.7	-0.14	-0.25	-0.07	0.57	-0.25	-0.46
Common Stock Shares Outstanding	0.64	0.58	0.94	0.18	-0.17	-0.5	-0.95	0.81	0.55	-0.24	-0.4	0.55	0.18		0.1	-0.21	0.81	0.94	0.95	0.64	0.9	-0.18	-0.3	0.1	-0.22	-0.49
Non Current Liabilities Total	-0.23	0.41	-0.07	-0.26	0.03	0.28	-0.17	-0.13	-0.29	0.03	-0.01	-0.29	-0.25	0.1		-0.19	0.56	0.11	-0.06	-0.22	0.34	-0.06	-0.35	-0.23	-0.05	0.0
Inventory	-0.16	-0.14	-0.2	-0.04	0.12	0.16	0.23	-0.26	-0.17	0.12	0.02	-0.17	-0.07	-0.21	-0.19		-0.26	-0.22	-0.27	-0.17	-0.02	-0.43	0.49	-0.08	-0.42	-0.02
Other Current Assets	0.53	0.45	0.74	0.2	-0.35	-0.45	-0.9	0.7	0.46	-0.41	-0.49	0.46	0.22	0.81	0.56	-0.26		0.87	0.73	0.56	0.8	-0.18	-0.41	0.2	-0.2	-0.6
Other Stockholder Equity	0.79	0.37	0.95	0.4	-0.38	-0.71	-0.99	0.93	0.74	-0.45	-0.55	0.74	0.37	0.94	0.11	-0.22	0.87		0.94	0.81	0.79	-0.25	-0.33	0.37	-0.28	-0.7
Total Liab	0.73	0.47	0.99	0.28	-0.22	-0.62	-0.94	0.93	0.67	-0.28	-0.42	0.67	0.23	0.95	-0.06	-0.27	0.73	0.94		0.73	0.79	-0.23	-0.21	0.29	-0.28	-0.55
Total Current Assets	0.99	0.04	0.75	0.84	-0.36	-0.98	-0.74	0.85	0.99	-0.42	-0.46	0.99	0.7	0.64	-0.22	-0.17	0.56	0.81	0.73		0.38	-0.24	-0.39	0.58	-0.26	-0.63
Short Term Debt	0.4	0.76	0.79	-0.04	0.05	-0.22	-0.82	0.58	0.28	-0.03	-0.28	0.28	-0.14	0.9	0.34	-0.02	0.8	0.79	0.79	0.38		-0.18	-0.29	-0.16	-0.22	-0.28
Intangible Assets	-0.28	-0.21	-0.23	-0.23	-0.12	0.2	0.24	-0.24	-0.22	-0.15	-0.19	-0.22	-0.25	-0.18	-0.06	-0.43	-0.18	-0.25	-0.23	-0.24	-0.18		-0.33	-0.24	0.99	0.34
Common Stock	-0.42	-0.37	-0.18	-0.43	-0.09	0.37	0.29	-0.13	-0.39	-0.04	0.03	-0.39	-0.07	-0.3	-0.35	0.49	-0.41	-0.33	-0.21	-0.39	-0.29	-0.33		0.17	-0.31	-0.08
Other Current Liab	0.49	-0.54	0.33	0.5	-0.68	-0.65	-0.35	0.59	0.6	-0.68	-0.56	0.6	0.57	0.1	-0.23	-0.08	0.2	0.37	0.29	0.58	-0.16	-0.24	0.17		-0.24	-0.73
Short Term Investments	-0.3	-0.23	-0.27	-0.23	-0.12	0.22	0.28	-0.27	-0.23	-0.14	-0.17	-0.23	-0.25	-0.22	-0.05	-0.42	-0.2	-0.28	-0.28	-0.26	-0.22	0.99	-0.31	-0.24		0.35
Current Deferred Revenue	-0.52	0.3	-0.6	-0.33	0.85	0.63	0.7	-0.76	-0.58	0.86	0.7	-0.58	-0.46	-0.49	0.0	-0.02	-0.6	-0.7	-0.55	-0.63	-0.28	0.34	-0.08	-0.73	0.35

Click cells to compare fundamentals

Cyclo Therapeutics Account Relationship Matchups

Cyclo Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.1M	14.2M	19.5M	4.2M	13.2M	13.9M
Total Current Liabilities	3.1M	3.7M	3.8M	3.5M	8.5M	8.9M
Total Stockholder Equity	936.0K	10.5M	15.7M	734.5K	4.8M	2.6M
Property Plant And Equipment Net	64.6K	87.9K	77.2K	56.7K	929.3K	505.7K
Net Debt	(2.7M)	(12.7M)	(16.4M)	(1.5M)	(8.2M)	(7.8M)
Retained Earnings	(25.1M)	(34.1M)	(48.3M)	(63.8M)	(83.9M)	(79.7M)
Accounts Payable	3.1M	3.5M	3.7M	2.2M	4.9M	5.1M
Cash	2.8M	12.8M	16.6M	1.5M	9.2M	9.7M
Non Current Assets Total	155.2K	137.7K	84.5K	56.7K	929.3K	694.6K
Non Currrent Assets Other	90.6K	49.8K	7.3K	(56.7K)	38.3K	36.4K
Cash And Short Term Investments	2.8M	12.8M	16.6M	1.5M	9.2M	9.7M
Net Receivables	182.5K	111.8K	539.1K	55.0K	122.4K	105.2K
Common Stock Shares Outstanding	1.1M	1.6M	6.4M	8.4M	16.3M	17.1M
Liabilities And Stockholders Equity	4.1M	14.2M	19.5M	4.2M	13.2M	13.9M
Non Current Liabilities Total	36.1K	62.9K	18.0K	3.5M	22.5K	21.4K
Inventory	242.6K	237.9K	227.4K	254.5K	254.4K	250.7K
Other Current Assets	749.2K	854.4K	2.1M	4.6M	2.7M	2.8M
Other Stockholder Equity	26.0M	44.5M	64.0M	64.5M	88.6M	93.0M
Total Liab	3.2M	3.7M	3.8M	3.5M	8.5M	8.9M
Total Current Assets	4.0M	14.1M	19.4M	4.2M	12.3M	12.9M
Common Stock	12.2K	477.0	841.0	849.0	2.9K	3.7K
Net Tangible Assets	936.0K	10.5M	15.7M	734.5K	844.7K	802.5K
Other Assets	129.7K	90.6K	49.8K	7.3K	6.6K	6.2K
Property Plant Equipment	64.6K	87.9K	77.2K	56.7K	65.2K	56.7K
Net Invested Capital	936.0K	10.6M	15.8M	734.5K	4.8M	5.5M
Property Plant And Equipment Gross	64.6K	87.9K	159.3K	158.2K	1.1M	1.1M
Net Working Capital	816.9K	10.4M	15.6M	677.9K	3.9M	5.2M
Capital Stock	12.2K	477.0	841.0	849.0	2.9K	3.5K

Currently Active Assets on Macroaxis

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft
HBI	Hanesbrands
STLD	Steel Dynamics

When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:

How To Invest In Cyclo

Details

Is Cyclo Stock a good investment?

Details

What is Cyclo Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.90)

Revenue Per Share

0.046

Quarterly Revenue Growth

0.051

Return On Assets

(2.82)

Return On Equity

(226.64)

The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclo Short Term Investments vs Other Current Liab Analysis

Short Term Investments vs Other Current Liab

Short Term Investments vs Other Current Liab Correlation Analysis

Correlation Coefficient

Short Term Investments

Other Current Liab

Cyclo Therapeutics fundamental ratios Correlations

Cyclo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cyclo Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Current Liabilities
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments

Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.96	Total Assets
Common Stock Shares Outstanding	- 0.95	Retained Earnings